KCK LTD.

CIK 1657662 · View on SEC EDGAR ↗

Portfolio value
$15.1M
#8,927 of 9,443 by 13F value · top 94.5%
Positions
2
As of
Sept. 30, 2025 Data as of Q3 2025

Portfolio value QoQ: -17.6% 13F does not disclose cash

Top 10 holdings weight
100.00%
Top 25 holdings weight
100.00%
Positions above 1%
1
Effective number of positions
1.0

Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)

Turnover Q3 2025: 0.0% Est. buys $0 · sells $0

Median holding: 4.0 quarters Tracked Q4 2024–Q3 2025 · 66.7% still held

New positions
0
Increased
0
Decreased
0
Closed
1
On this page

Performance vs S&P 500

Tracked Q4 2024–Q3 2025
+43.7%
S&P 500 total return (same window)
+13.4%
Excess return
+30.4%

Annualized: +62.4% · S&P 500: +18.3%

Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.

Priceable coverage: 100.0% · Options excluded: 0.0%

Sector breakdown

Health Care
100.0%

Full portfolio 2 positions

Type Streak 8Q trend
SGHT Sight Sciences, Inc. - Common Stock $15,049,914 99.66% 4,374,975 $-3,018,733
RNTX Rein Therapeutics, Inc. - Common Stock $52,055 0.34% 22,341 $-196,824

Top movers (QoQ)

Security Action Shares Δ Value Δ
SGHT Price move only +0 -$3.0M
RNTX Price move only +0 -$197K

Exited positions

Includes corporate events (mergers, delistings) — not all exits are sells

Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.

SecurityQuarter Shares before Value before Price since exit
NPCE March 31, 2025 5,270,845 $58,980,756 22.7%